Evidence map›Paper›PMID 42492521›Full record

ArticleCell reports. Medicine2026

Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice.

Bingfeng Zuo, Xuening Liu, Zheng Zhang, Zhenqiang Xu, Yanzhi Zhong, Yang Zhang, Qian Yang, Zezhen Yu, Kangjie Zhao, Yali Zhang and 2 more

Abstract read
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bingfeng ZuoState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China.
Xuening LiuState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China.
Zheng ZhangState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China; Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China.
Zhenqiang XuState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China.
Yanzhi ZhongState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China.
Yang ZhangState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China.
Qian YangState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China.
Zezhen YuState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China.
Kangjie ZhaoState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China.
Yali ZhangState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China.
Yiqi SeowGenome Institute of Singapore (GIS), Agency for Science, Technology and Research (ASTAR), 60 Biopolis Street, Genome, Singapore 138672, Republic of Singapore.
HaiFang YinState Key Laboratory of Experimental Hematology & the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics & Division of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road, Heping District, Tianjin 300070, China. Electronic address: haifangyin@tmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unresectable hepatocellular carcinoma (HCC) demands more effective therapeutics to overcome its dismal prognosis. Dendritic cell (DC)-derived exosomes (DEXs) modified with CP05-anchored HCC-targeting peptide (P47-P), DC-recruiting and -activating high-mobility group nucleosome-binding protein 1 (HMGN1) (N1ND-N), and lymphotactin domains (XCL1-X) make DEX

Indexed as

Cancer VaccinesCarcinoma, HepatocellularExosomesImmune Checkpoint InhibitorsLiver NeoplasmsPhenylurea CompoundsProgrammed Cell Death 1 ReceptorQuinolinesAnimalsCD8-Positive T-LymphocytesDendritic CellsHumansMiceMice, Inbred C57BLCancer VaccinesImmune Checkpoint InhibitorslenvatinibPhenylurea CompoundsProgrammed Cell Death 1 ReceptorQuinolinesanti-PD-1exosomehepatocellular carcinomalenvatinibpersonalized immunotherapy

Identifiers

PMID42492521
PMCPMC13522765

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.